AZ enters agreement w/ Perrigo for Entocort in US
ASTRAZENECA ENTERS INTO AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US Divestment further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015 AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus. Under the terms of the agreement, Perrigo will pay AstraZeneca $380 million upon